NAMITA PURAN: Open Payments
NPI 1619591245 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$453 in 18 payments from 10 companies in 2025. Trend: 2023 $47 · 2024 $308 · 2025 $453
Food & beverage: $343Education: $110
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC | 5 | $129 |
| Lilly USA, LLC | 2 | $116 |
| Novartis Pharmaceuticals Corporation | 2 | $44 |
| Caris MPI, Inc. | 2 | $38 |
| Gilead Sciences, Inc. | 2 | $25 |
| Stemline Therapeutics Inc. | 1 | $25 |
| Incyte Corporation | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $20 |
| TerSera Therapeutics LLC | 1 | $18 |
| Janssen Biotech, Inc. | 1 | $17 |
Products named: KEYTRUDA, MI CANCER SEEK, VERZENIO, Orserdu, SCEMBLIX, ZYNYZ, Enhertu, KISQALI.
Industry payments across DC — which companies pay providers there.
